» Articles » PMID: 38348029

Concurrence of Dermatomyositis and Psoriasis: a Case Report and Literature Review

Overview
Journal Front Immunol
Date 2024 Feb 13
PMID 38348029
Authors
Affiliations
Soon will be listed here.
Abstract

Dermatomyositis (DM) is a type of inflammatory myopathy with unknown causes. It is characterized by distinct skin lesions, weakness in the muscles close to the body, and the potential to affect multiple organs. Additionally, it may be associated with the presence of malignancies. The development of DM is influenced by genetic susceptibility, autoimmune response, and various external factors like cancer, drugs, and infectious agents. Psoriasis is a chronic, recurring, inflammatory, and systemic condition. Scaly erythema or plaque is the typical skin manifestation. The etiology of psoriasis involves genetic, immune, environmental and other factors. It is uncommon for a patient to have both of these diseases simultaneously, although individuals with DM may occasionally exhibit symptoms similar to those of psoriasis. Our patient was diagnosed with psoriasis in his 50s because of scalp squamous plaques, but he did not receive standard treatment. Ten years later, he developed symptoms of muscle pain and limb weakness. He was diagnosed with psoriasis complicated with dermatomyositis in our department and received corresponding treatment. Moreover, we reviewed the relevant literature to evaluate similarities and differences in clinical manifestation and treatment to other cases.

Citing Articles

Increased Risk of Dermatomyositis in Patients with Psoriasis: A Retrospective Cohort Study.

Chen M, Tian N, Cui R, Zhang H, Wang Q, Tong Q Immunotargets Ther. 2025; 14:139-149.

PMID: 40046035 PMC: 11881606. DOI: 10.2147/ITT.S500811.


Understanding the Intricate Pathophysiology of Psoriasis and Related Skin Disorders.

Orzan O, Tutunaru C, Ianosi S Int J Mol Sci. 2025; 26(2).

PMID: 39859462 PMC: 11766135. DOI: 10.3390/ijms26020749.

References
1.
DeWane M, Waldman R, Lu J . Dermatomyositis: Clinical features and pathogenesis. J Am Acad Dermatol. 2019; 82(2):267-281. DOI: 10.1016/j.jaad.2019.06.1309. View

2.
Johnson-Huang L, Suarez-Farinas M, Sullivan-Whalen M, Gilleaudeau P, Krueger J, Lowes M . Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol. 2010; 130(11):2654-63. PMC: 2955161. DOI: 10.1038/jid.2010.166. View

3.
Dastmalchi M, Grundtman C, Alexanderson H, Mavragani C, Einarsdottir H, Helmers S . A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis. 2008; 67(12):1670-7. DOI: 10.1136/ard.2007.077974. View

4.
Furst D, Amato A, Iorga S, Gajria K, Fernandes A . Epidemiology of adult idiopathic inflammatory myopathies in a U.S. managed care plan. Muscle Nerve. 2012; 45(5):676-83. DOI: 10.1002/mus.23302. View

5.
Aggarwal R, Charles-Schoeman C, Schessl J, Bata-Csorgo Z, Dimachkie M, Griger Z . Trial of Intravenous Immune Globulin in Dermatomyositis. N Engl J Med. 2022; 387(14):1264-1278. DOI: 10.1056/NEJMoa2117912. View